

CHAPTER 17

PCR-based methods to determine DNA methylation status at specific CpG sites using methylation-sensitive restriction enzymes


Helmtrud I. Roach and Ko Hashimoto

1. INTRODUCTION

In recent years, there has been an explosion of interest in epigenetics, which refers to heritable changes in gene expression without alteration in the DNA sequence. The major epigenetic changes are histone acetylation and DNA methylation. Methylation takes place at cytosines that are adjacent to guanines, the so-called CpG sites. However, very little information is available on the methylation status of particular CpG sites in the promoter regions of specific genes from different cell types or cells from different developmental stages. This is due to several factors:

1. While DNA sequence analysis can be carried out on DNA extracted from any cell in the body, the methylation status for a particular gene is cell-type specific and thus needs to be analyzed separately for each tissue.
2. As PCR amplifications eliminate all CpG methylation, it is necessary to obtain sufficient genomic DNA directly from the relevant tissue/cells rather than by amplification of specific DNA segments.
3. Although the bisulfite modification method of detecting the presence or absence of methylation (see Chapter 16) gives valuable results, it is not best suited in all instances.

On the whole, conformationally relaxed chromatin (euchromatin) indicates transcriptionally active regions and is associated with hypomethylated DNA and acetylated histones, whereas compact chromatin (heterochromatin) is transcriptionally silent, hypermethylated, and bound to nonacetylated histones. DNA methylation is thus one of the principal mechanisms by which cells maintain



a stable chromatin configuration that regulates transcription. For further details, see (1–6).

2. METHODS AND APPROACHES

2.1 Methylation-sensitive restriction enzymes (MSREs)

The methylation sensitivity of certain restriction enzymes provides an elegant and straightforward method of assessing methylation status of specific CpG sites. There are over 50 such enzymes (see *Table 1*), all of which have at least one CpG site within their recognition sequence. However, the cleavage site is not necessarily within the CpG site or within the recognition sequence, as illustrated for *BceAI* below, where the cleavage site is 12 bp downstream from the last base of the recognition sequence for the top strand and 14 bp upstream for the complementary strand:




Table 1. Recognition sequences and sites of cleavage of commercially available MRSEs

In some cases, the cleavage site is some distance away from the recognition site. In this case, the numbers in parentheses indicate the distance between the last given nucleotide and the cleavage site. The first number is for the 5'→3' strand and the second for the complementary strand. W = A or T; Y = C or T; R = G or A. From: <http://rebase.neb.com/rebase/rebase.html>.

| Enzyme | Site | Enzyme | Site | Enzyme | Site | Enzyme | Site |
|--------------|---------------|---------------|----------------|-----------------|--------------|---------------|-----------|
| <i>AatII</i> | GACGT↓C | <i>BsmBI</i> | CGTCTC (1/5) | <i>Haell</i> | RGCgc↓Y | <i>NruI</i> | TCG↓CGA |
| <i>AcI</i> | C↓CGC | <i>BspDI</i> | AT↓CGAT | <i>Hgal</i> | GACGC (5/10) | <i>PaeR7I</i> | C↓TCGAG |
| <i>AclI</i> | AA↓CGTT | <i>BspEI</i> | T↓CCGGAA | <i>Hhal</i> | GCG↓C | <i>PmlI</i> | CAC↓GTG |
| <i>AfeI</i> | AGC↓GCT | <i>BsrBI</i> | CCGCTC (-3/-3) | <i>HinP1I</i> | G↓CGC | <i>PvuI</i> | CGATØCG |
| <i>AgI</i> | A↓CCGGT | <i>BsrFI</i> | R↓CCGGY | <i>HpaII</i> | C↓CGG | <i>RsrII</i> | CG↓GWCCG |
| <i>Ascl</i> | GG↓CGCGCC | <i>BssHII</i> | G↓CGCGC | <i>Hpy99I</i> | CGWCG↓ | <i>SacII</i> | CCGC↓GG |
| <i>Asl</i> | GCGAT↓CGC | <i>BstBI</i> | TT↓CGAA | <i>HpyCH4IV</i> | A↓CGT | <i>SalI</i> | G↓TCGAC |
| <i>AvaI</i> | C↓YCGRG | <i>BstUI</i> | CG↓CG | <i>KasI</i> | G↓GCGCC | <i>SfI</i> | GGC↓GCC |
| <i>BceAI</i> | ACGGC (12/14) | <i>ClaI</i> | AT↓CGAT | <i>MluI</i> | A↓CGCGT | <i>SgrAI</i> | CR↓CCGGYG |
| <i>BmgBI</i> | CAC↓GTC | <i>EagI</i> | C↓GGCCG | <i>Nael</i> | GCC↓GTC | <i>SmaI</i> | CCC↓GGG |
| <i>BsaAI</i> | YAC↓GTR | <i>FauI</i> | CCCGC (4/6) | <i>NarI</i> | GG↓CGCC | <i>SnaBI</i> | TAC↓GTA |
| <i>BsaHI</i> | GR↓CGYC | <i>FseI</i> | GGCCGG↓CC | <i>NgoMIV</i> | G↓CCGGC | <i>TliI</i> | C↓TCGAG |
| <i>BsiEI</i> | CGRY↓CG | <i>FspI</i> | TGC↓GCA | <i>NotI</i> | GC↓GGCCGC | <i>XbaI</i> | C↓TCGAG |
| <i>BsWI</i> | C↓GTACG | | | | | | |







Figure 1. Principles of the MRSE assay for methylation status at specific CpG sites. In the absence of methylation (left), DNA is cleaved and cannot be amplified by PCR. In the presence of methylation (right), the DNA remains intact and can be amplified with suitable primer pairs.





2.2 Principle of the MSRE PCR method

The principle of this method is illustrated in *Fig. 1*. If the cytosine of a specific CpG site is not methylated, then the enzymes cleave as expected. However, if the cytosine of the CpG is methylated, then the enzymes cannot cleave and the DNA remains intact. By designing suitable primer pairs that bracket the region of interest, the presence or absence of methylation can be determined by the presence or absence of a PCR band following enzymatic digestion. The MSRE method is relatively easy and is particularly suitable for promoters with a limited number of CpG sites and if only small quantities of DNA are available. There are, however, two points for consideration:

- MSREs might not be available for a specific CpG site of interest.
- There may be several CpG sites cut by the same MSRE within the PCR-amplified region.

The latter is a particular problem for CpG island promoters, where the concentration of CpGs is very high and will require careful primer design (see section 2.3). However, if the aim is preliminary scanning of CpGs, for example to provide 'proof of concept' data that a change in methylation has taken place somewhere, then the MSRE method will provide useful results.





2.3 Identifying CpG sites and suitable MSREs

To find the promoter region sequence for the gene of interest, we recommend using the National Center for Biotechnology Information (NCBI) website (<http://www.ncbi.nlm.nih.gov/>).

- Select the 'Gene' option in the drop-down search box on the left. Type in the name of the gene of interest and then select the appropriate species from the list given. Scroll down to the section titled 'Related sequences', which, in most cases, will provide a list of accession numbers for genomic DNA. Clicking on the separate accession numbers should identify a file containing 1000–2000 bp of sequence upstream of the transcription start site, which corresponds to the promoter. Knowledge of the characteristics of the promoter will help to identify the most relevant area. If this information is not available, concentrate initially on the sequence ~1000 bp upstream of exon 1.
- Copy the sequence into Microsoft Word, then use the 'Find/replace' facility to mark all 'CG's by replacing them with **CG** (in bold, larger font and maybe change the color to red). Do the same for 'C G', then scan the right-hand edge for single Cs and determine whether the next line contains a 'G'. This will immediately give you useful information about whether the promoter contains a CpG island (many closely spaced CpG sites) or is a sparse CpG promoter.
- To find out which MSREs cut your sequence, go to <http://www.restrictionmapper.org/> and select all 53 MSREs (listed in *Table 1*).
- Paste your sequence of interest into the box in the 'Sequence Info' section and click on 'Map sites'. This will generate a list of MSREs that cut within your sequence and their cut positions. If you have more than one sequence to map, it is useful to do this straight away, as the program remembers the selected MSREs. Use the information to map the cut positions onto your sequence.
- Design PCR primers to bracket the region of interest. Primers should be located in regions with no CpG sites. An example of a sparse CpG promoter is the matrix metalloproteinase 13 (MMP-13) gene promoter, shown diagrammatically in *Fig. 2*. For this gene, the methylation status has been determined successfully for six out of the ten CpG sites in a 600 bp promoter region (7), using unique enzyme/primer combinations.






Figure 2. Example of a promoter suitable for the MSRE assay.

Ten CpG sites, cut by four different enzymes, are present within a 550 bp promoter region upstream from the transcription start site of MMP-13. Six of these sites (plus one in the coding region) can be assessed uniquely by various enzyme/primer combinations. However, four sites cannot be examined, as no MSREs are available to cut at these sites. The *Aval* site at -136 was only evaluated with primers MMP-13b, *Hpy*, *HpyCH4IV*.

2.4 Extraction of nucleic acids

In most studies, the aim is to link DNA methylation status directly to mRNA expression, for example, to determine whether loss of methylation at a particular CpG site is associated with induction of gene expression. In this case, simultaneous extraction of genomic DNA and RNA from the same specimen is highly desirable. However, in practice, this is not always possible. A particular problem arises if the tissue contains a lot of extracellular matrix with relatively few cells, as is the case for adult articular cartilage or muscle fibers. There are many commercially available kits (e.g. Qiagen) for the extraction of either RNA or DNA. However, combined kits for simultaneous RNA and DNA extraction are so far only available as microkits suitable for cells, not for whole tissues.

If DNA (or RNA) is to be extracted directly from whole tissues, a freezer mill is ideal to grind the tissue under liquid nitrogen into a fine powder (see *Protocol 1*). We have successfully used the Spex Certiprep 6750 for grinding human articular cartilage.



Protocol 1

Preparation of tissue for DNA or RNA extraction using a freezer mill

Equipment and Reagents

- Freezer mill (Spex Certiprep or similar)
- 10 ml Sterile tube
- Small spatula (to scoop out smashed specimen)
- Weighing scales

Method

1. Work in a well-ventilated room.
2. Pre-cool the freezer mill as instructed by the manufacturer.
3. Pour liquid nitrogen into the freezer mill^a. Close the lid slowly to avoid spitting of the liquid nitrogen, as it boils vigorously the first time it is poured.
4. Weigh a 10 ml sterile tube.
5. Transfer samples into freezer mill cylinders with a metal rod, pre-cool, and run the milling cycles as instructed. Two samples can be pre-cooled while the first is being milled.
6. Scoop out the smashed samples and put them into the 10 ml tube using the spatula^b.
7. Reweigh the tube and calculate the milled weight of the sample (100–500 mg is ideal)^c.
8. Add lysis buffer as used in the DNA or RNA extraction kit and store the sample at –20°C or proceed directly to nucleic acid extraction (see *Protocol 2*).
9. Wash the cylinders and prepare the next samples.

Notes


^aWear a long-sleeved laboratory coat, cryo-resistant gloves, and goggles when handling liquid nitrogen.


^bThe yield of milled powder may be low as some sample inevitably remains inside the cylinder or attached to the metal rods. If complete recovery of the sample is critical, lysis buffer may be added directly to the mill cylinders.

^cIf both RNA and DNA are to be extracted from the same sample, it is best to split the milled powder into two and then use a maxi or midi kit for RNA or DNA, respectively. Alternatively, isolate the cells from the tissue prior to RNA/DNA extraction, as in *Protocol 2*.

2.4.1 Simultaneous extraction of RNA and DNA from cells

Depending on the tissue, it may be possible to isolate the cells from their matrix prior to DNA or RNA extraction. This has the advantage that no freezer mill is required and kits for simultaneous extraction of RNA and DNA can be used (see *Protocol 2*).





Protocol 2

Simultaneous extraction of RNA and DNA from cells

Equipment and Reagents

- AllPrep DNA/RNA mini kit (Qiagen)
- High-speed centrifuge
- 2-Mercaptoethanol (Sigma)
- 70% Ethanol
- DNase I (Qiagen)

Method

1. The initial number of cells should not exceed 1×10^7 cells and it recommended to start with approximately 3×10^6 to 4×10^6 cells^{a,b}.
2. Add 2-mercaptoethanol or ethanol to the relevant buffers following the manufacturer's instructions.
3. Add 350–600 ml^c of lysis buffer to 3×10^6 to 1×10^7 cells. Vortex and pass the lysate at least five times through a 20-gauge needle fitted to an RNase-free syringe, which homogenizes the cells.
4. Apply the lysate to an AllPrep DNA spin column placed in a 2 ml collection tube. Genomic DNA will bind to the DNA spin column.
5. Centrifuge for 1 min at $\geq 10\,000$ r.p.m. at room temperature.
6. Place the AllPrep DNA spin column in a new 2 ml collection tube and store at 4°C for later DNA purification. The flow-through will contain RNA.
7. RNA and DNA can be purified from the flow-through and spin column, respectively, following the manufacturer's instructions.
8. If possible, reverse transcribe the RNA immediately^d.
9. Quantify the RNA and DNA using a spectrophotometer^e.

Notes

^aIn human articular cartilage, cells only represent 3–5% of the tissue. Cells can be isolated by sequential treatment with:

- Trypsin (10% in PBS) for 30 min at 37°C
- Hyaluronidase (1 mg/ml in PBS) for 15 min at 37°C
- Collagenase B (10 mg/ml, Roche) for 12–15 h


The cells can then be washed in PBS and the cell suspension filtered through a sterile 70 μm sterile cell strainer, followed by centrifugation for 5 min at 1700 r.p.m. The main steps in this procedure are summarized in *Fig. 3*.

^bIn practice, a confluent T25 flask provides just enough cells, whilst a confluent T80 flask is ample.

^cThe volume of lysis buffer and wash buffer depends on the number of starting cells: for up to 3×10^6 cells use 350 ml of lysis buffer, and for up to 1×10^7 cells use 600 ml of lysis buffer.

^dIt is highly advisable to reverse transcribe RNA immediately into cDNA, which only takes a further 1.5 h. Alternatively, RNA can be frozen at -80°C .

^eQuantification of RNA with the spectrophotometer often gives a low reading. This is because the RNA spin column preferentially binds mRNA, whereas small ribosomal RNA flows through. When total RNA is extracted by the Trizol method, the majority of RNA is ribosomal, which can easily be quantified. Using the column method, good PCR bands are often obtained even when the RNA released from the spin column cannot be quantified.



286 ■ CHAPTER 17: PCR-BASED METHODS TO DETERMINE DNA METHYLATION STATUS






Figure 3. Schematic flow diagram of the steps in the simultaneous extraction of RNA and genomic DNA from the same specimen.

2.5 Detection of methylation status using MSREs

Although the bisulfite modification method has been used more extensively for determining methylation status, several groups have successfully used the MSRE PCR method (see *Protocols 3 and 4*) (7–9).





Protocol 3

Restriction enzyme digest

Equipment and Reagents

- Genomic DNA (5–10 ng/μl)
- Thermal cycler with heated lid^a or water bath (37 or 65°C)
- Restriction enzyme(s)
- Relevant buffer and 100× bovine serum albumin (BSA) if required (New England Biolabs or similar)
- PCR-grade DNase/RNase-free water
- PCR tubes, pipettes, and tips

Method


1. Check the concentration of supplied enzyme. For a 10 μl reaction, ~2–4 units are required^b.
2. For each reaction, set up^c:
 - 9 μl of extracted genomic DNA (5 ng/μl)
 - 1 μl of 10× buffer
 - 0.1 μl of 100× BSA (if required)
 - 0.2–2 μl of restriction enzyme, containing 2–4 units of activity
3. For each specimen, set up a parallel sample, omitting the enzyme. This will be the no-enzyme control for the PCR.
4. Incubate at the recommended temperature for the enzyme (usually 37°C) for the recommended time (usually overnight).
5. To denature the enzyme, heat at 65°C (some enzymes need 80°C or cooling at 4°C) for 10–20 min.
6. Enzyme-treated DNA may be stored for up to 1 week at 4°C, but it is best to carry out the PCR immediately after enzyme digestion.


Notes

^aThe heated lid of a thermal cycler prevents condensation of the reaction mixture on the lid of the tube, which may be a problem in a water bath or incubator.

^bToo much enzyme or incubation for too long increases nonspecific digestion, whilst digestion will not be complete when using too little enzyme or too short a time interval. Hence, it is essential to perform preliminary studies for each enzyme, using universally methylated DNA (Chemicon International, cat. no. S7821) or universally nonmethylated DNA. The latter can be obtained, using the GenomiPhi v2 DNA amplification kit (GE Healthcare Life Sciences).

^cIf several samples are to be treated with the same restriction enzyme, it may be useful to prepare a 'master mix' of enzyme, buffer, and BSA.





Protocol 4

PCR

Equipment and Reagents

- Digested DNA from *Protocol 3*
- Platinum PCR SuperMix (Invitrogen) containing PCR buffer, MgCl₂, and dNTPs
- Oligonucleotides (10 µM)
- Thermal cycler
- 2% Agarose gel containing 10 ng/ml ethidium bromide
- 6× Orange loading dye solution (Fermentas)
- Equipment and reagents for agarose gel electrophoresis including 1× TBE agarose gel running buffer (10.8 g/l Tris base; 5.5 g/l boric acid; 4 ml/l 0.5 M EDTA, pH 8.0, diluted from a 10× stock; Sigma)
- DNA size marker (100 bp ladder; Invitrogen)
- UV light source


Method

1. Combine per 25 µl reaction (it is not necessary to have a 50 µl reaction mixture, as recommended by the Invitrogen protocol):
 - 23 µl Platinum PCR SuperMix
 - 0.5 µl of each forward and reverse primer
 - 1 µl of DNA^a
2. Mix briefly by vortexing or pipetting. Centrifuge at 12 000 *g* for 5–10 s to consolidate the sample.
3. Amplify the DNA using the following PCR profile:
 - 94°C for 2 min
 - 35 cycles of 94°C for 30 s, annealing using at a primer-dependent temperature for 30 s, and 72°C for 1 min
 - 72°C for 5 min
4. Analyze the PCR products by mixing 10 µl of the reaction mix with 1 µl of 6× orange loading dye solution and resolving the sample by agarose gel electrophoresis alongside a DNA size marker^b.

Notes

^aIt is important to PCR amplify the no-enzyme control DNA in order to assess the effect of enzymatic digestion on the PCR. A negative control is also essential to determine any possible PCR contamination.

^bThe assessment of methylation status depends on the difference in intensity between the band from enzyme-digested and that of the no-enzyme control. In an ideal specimen, a strong band is present in the no-enzyme control, whilst no band is detectable in the corresponding enzyme-digested sample.



2.6 Applications

In normal adult articular cartilage, the expression of proteases, such as MMP-13, is silenced. However, in osteoarthritis, many cartilage cells abnormally produce the enzyme, as has been shown by immunocytochemistry. Moreover, this abnormal expression is stably transmitted to daughter cells. These observations suggest that demethylation at some CpG sites in the promoter of the MMP-13 might have 'unsilenced' the gene and thus permitted abnormal expression of the protease. To test this hypothesis, genomic DNA isolated directly from human articular cartilage was subject to MRSE analysis for MMP-13. As can be seen in *Fig. 4*, all sites were fully methylated in control cartilage, but loss of DNA methylation was found at two CpG sites at -110 and -136 bp in the osteoarthritic specimen. When 16 osteoarthritis samples were compared with ten controls, demethylation at the *Hpy*CH4IV-cleavable site at -110 bp was present in the majority of osteoarthritis samples (7), which suggests that this particular CpG site may be important in the epigenetic 'unsilencing' of gene expression.





Figure 4. PCR of genomic DNA after treatment with MRSEs.

Results are shown for the promoter region of MMP-13 in normal articular cartilage (top row) compared with osteoarthritic cartilage (bottom row). All of the CpG sites in normal articular cartilage are methylated, as indicated by the presence of PCR bands. Many of these CpG sites are also methylated in the osteoarthritic sample (asterisks). However, loss of methylation could be demonstrated in many osteoarthritic patients at the *Aval* site at -134 bp and the *Hpy*CH4IV site at -110 bp (arrows). Reprinted with permission from (7).

In parallel experiments, reverse transcriptase PCR demonstrated clear induction of MMP-13 in osteoarthritis samples with no expression in control (fracture neck of femur, #NOF) samples (see *Fig. 5*). MRSE analysis of the same samples using the *Hpy*CH4IV-cleavable site at -110 bp identified clear PCR bands for the controls (methylated, not susceptible to digestion; albeit reduced in intensity compared with undigested samples), whilst the corresponding bands were either very weak or absent in the osteoarthritic samples (unmethylated, susceptible to digestion). Although this example demonstrates the correlation between methylation and



290 ■ CHAPTER 17: PCR-BASED METHODS TO DETERMINE DNA METHYLATION STATUS




Figure 5. Combined determination of mRNA expression (top) and DNA methylation status (bottom).

Results are shown for two control samples, obtained from patients who had sustained a fracture of the neck of the femur (#NOF), and two osteoarthritic patients (OA). MMP-13 (M13) expression was absent in the control samples, but present in the OA samples. After digestion with *HypCH4IV* (hyp4) and PCR, a band was still present in the control samples, but was either very weak or absent in the OA samples. GPDH, glyceraldehyde 3-phosphate dehydrogenase; C, no-enzyme control for methylation status.

expression, it also pinpoints some of the problems of using conventional PCR for methylation detection (see section 3). The reduced intensity of the PCR bands for control samples could have been due to overdigestion or loss of methylation in some cells. In the latter case, this loss of methylation obviously was not yet sufficient to induce gene transcription. In the first osteoarthritis sample (OA1), a faint band was still present, but was very weak compared with the no-enzyme control. We would interpret this as absence of methylation.

3. TROUBLESHOOTING

- **A band is still present after enzyme digestion for the no-methylation control**
As this negative control is universally unmethylated, one would expect an absence of bands for all enzyme/primer combinations. If a PCR band is still seen, then the conditions for enzyme digestion were not sufficient to produce complete digestion. Increase the enzyme concentration or the length of digestion (but see overdigestion below). As PCR is involved, a reduction in the number of cycles may also be beneficial.
- **Loss of band intensity is observed in the methylated control**
As this control is universally methylated, one should not see any significant loss in band intensity after enzyme digestion. However, in practice we nearly

always observe some loss in intensity, presumably due to nonspecific DNA degradation. If the PCR band is considerably reduced in intensity compared with the no-enzyme control, then there is too much nonspecific degradation, possibly following overdigestion. Reduce the enzyme concentration or the length of digestion.

- **In a specimen where loss of methylation would be expected, a weak band is still visible**

If conditions have been optimized using the positive and negative DNA controls, the presence of a weak band in enzyme-treated samples may be due in part to the nature of PCR and in part to the heterogeneity of the cells. If a strong band is found in the no-enzyme control together with a weak band in the enzyme-treated sample, a reduction in the number of PCR cycles may eliminate the weak band, whilst still showing the presence of a band in the no-enzyme control.

- **Heterogeneity of the cells with respect to the methylation status of a particular CpG site**


This is a problem in both the MSRE PCR and the bisulfite modification methods. In any one cell, a particular CpG site is either methylated or not methylated, but this methylation status may vary within the cell population. For example, assume that a particular gene is induced in a specific situation so that 30% of the cells express this gene. Reverse transcriptase PCR will easily demonstrate expression where there was none prior to induction. Let us further assume that the induction was associated with loss of methylation at a specific CpG site, i.e. this CpG site had become demethylated in 30% of the cells. However, as this CpG site is still methylated in 70% of the cells, a strong PCR band would be present. Thus, it would be impossible to demonstrate changes in methylation status, even though these were present. To overcome these difficulties, we would recommend developing real-time PCR assays to measure the degree of methylation.

- **No PCR band is visible in the no-enzyme control**

If the total amount of genomic DNA is too low, no PCR band may be visible in the no-enzyme control. In this case, either amplify for a further 5–10 cycles (recommended if a very faint band is visible) or use the PCR product for a further round of 30–35 cycles of PCR using the same primers. This is quite successful for most primers, but nonspecific amplification and additional random bands can also occur. In this case, design nested primers for the second round of PCR to amplify a region just inside the first primer product. This will usually eliminate the spurious additional bands.

4. REFERENCES

1. Roach HI & Aigner T (2006) *Osteoarthritis Cartilage*, **15**, 128–137.
- ★★ 2. Rodenhiser D & Mann M (2006) *CMAJ*, **174**, 341–348. – *A good review of the epigenetic literature in a clinical setting.*
3. Kress C, Thomassin H & Grange T (2001) *FEBS Lett.* **494**, 135–140.
4. Hendrich B & Tweedie S (2003) *Trends Genet.* **19**, 269–277.



292 ■ CHAPTER 17: PCR-BASED METHODS TO DETERMINE DNA METHYLATION STATUS

5. Fuks F (2005) *Curr. Opin. Genet. Dev.* **15**, 490–495.
6. Davis CD & Uthus EO (2004) *Exp. Biol. Med. (Maywood)* **229**, 988–995.
7. Roach HI, Yamada N, Cheung KS, et al. (2005) *Arthritis Rheum.* **52**, 3110–3124. – A good review of the methods described in this chapter.
8. Singer-Sam J, Goldstein L, Dai A, Gartler SM & Riggs AD (1992) *Proc. Natl. Acad. Sci. U.S.A.* **89**, 1413–1417.
9. Pogribny IP, Pogribna M, Christman JK & James SJ (2000) *Cancer Res.* **60**, 588–594.

